JAK Inhibitors’ Cancer Risk Confirmed in Real-World Data

(MedPage Today) — Use of Janus kinase (JAK) inhibitors for rheumatoid arthritis (RA) was associated with significantly higher rates of malignancies compared with biologic agents, data from a large German registry indicated.
Based on more than…